Skip to main
CBIO

GlycoMimetics Inc (CBIO) Stock Forecast & Price Target

GlycoMimetics Inc (CBIO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Crescent Biopharma is downgraded to Neutral amidst the competitive sacituzumab tirumotecan (sac-TMT) and pembrolizumab regimen, which showed a stronger efficacy profile compared to CR-001 in the key 1L NSCLC comparison. The lower risk of progression or death and higher response rate of sac-TMT make it a more compelling option than CR-001. Additionally, the immature survival data of CR-001 also weakens its premium positioning, leading to the decision to downgrade to Neutral.

Bears say

Crescent Biopharma is facing significant competition in the development of its pipeline products, particularly CR-001, which is targeting the same PD-1/VEGF pathway as other companies such as Akeso Biopharma and Summit Therapeutics. The recent data from Pfizer's ASCO update for its ITGB6-directed ADC in combination with pembrolizumab showed a strong response rate, indicating that Crescent's CR-003/SKB105 program may not offer a significant improvement over existing treatments. This, coupled with the lack of attributed value to their ADC programs, presents risks for Crescent, and their stock carries a negative outlook.

GlycoMimetics Inc (CBIO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GlycoMimetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GlycoMimetics Inc (CBIO) Forecast

Analysts have given GlycoMimetics Inc (CBIO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, GlycoMimetics Inc (CBIO) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GlycoMimetics Inc (CBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.